Concord Drugs Ltd
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on
approved formulations
- Market Cap ₹ 88.0 Cr.
- Current Price ₹ 88.0
- High / Low ₹ 92.5 / 26.1
- Stock P/E 152
- Book Value ₹ 34.4
- Dividend Yield 0.00 %
- ROCE 5.20 %
- ROE 1.00 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.56 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.86% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 58.96 | 52.08 | 44.92 | 45.24 | 45.08 | |
| 53.37 | 47.51 | 40.88 | 41.10 | 40.51 | |
| Operating Profit | 5.59 | 4.57 | 4.04 | 4.14 | 4.57 |
| OPM % | 9.48% | 8.77% | 8.99% | 9.15% | 10.14% |
| 0.10 | 0.01 | 0.01 | 0.01 | 0.00 | |
| Interest | 1.68 | 1.71 | 1.87 | 2.03 | 2.09 |
| Depreciation | 1.76 | 1.63 | 1.56 | 1.43 | 1.46 |
| Profit before tax | 2.25 | 1.24 | 0.62 | 0.69 | 1.02 |
| Tax % | 28.89% | 20.97% | 25.81% | 50.72% | |
| 1.59 | 0.99 | 0.47 | 0.34 | 0.58 | |
| EPS in Rs | 1.82 | 1.06 | 0.47 | 0.34 | 0.58 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -8% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -40% |
| TTM: | 214% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 31% |
| 3 Years: | 40% |
| 1 Year: | 140% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 8.74 | 9.32 | 10.00 | 10.00 | 10.00 |
| Reserves | 19.62 | 22.38 | 23.82 | 24.11 | 24.42 |
| 16.43 | 16.96 | 17.52 | 19.24 | 17.09 | |
| 11.66 | 9.57 | 7.46 | 11.80 | 17.10 | |
| Total Liabilities | 56.45 | 58.23 | 58.80 | 65.15 | 68.61 |
| 13.97 | 12.92 | 11.68 | 12.21 | 11.51 | |
| CWIP | 0.55 | 0.92 | 1.63 | 2.00 | 2.05 |
| Investments | 0.00 | 0.89 | 0.84 | 0.80 | 0.80 |
| 41.93 | 43.50 | 44.65 | 50.14 | 54.25 | |
| Total Assets | 56.45 | 58.23 | 58.80 | 65.15 | 68.61 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.77 | 1.66 | 0.79 | 3.72 | |
| -2.44 | -2.27 | -1.01 | -2.32 | |
| 1.68 | 0.62 | 0.28 | -1.43 | |
| Net Cash Flow | 0.01 | 0.02 | 0.07 | -0.02 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 141.52 | 110.80 | 103.44 | 109.73 |
| Inventory Days | 151.64 | 178.58 | 251.53 | 261.81 |
| Days Payable | 62.25 | 46.92 | 34.02 | 78.95 |
| Cash Conversion Cycle | 230.90 | 242.47 | 320.95 | 292.59 |
| Working Capital Days | 112.48 | 152.43 | 132.77 | 115.78 |
| ROCE % | 6.31% | 4.98% | 5.20% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Nov
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Nov
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Nov
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
24 Nov - Preferential allotment on 20-11-2025: promoters allotted equity shares and warrants, increasing holdings.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
22 Nov - New Paper publication of financial results for Quarter and Half year ended 30 Sep,2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Product Portfolio:[1]
a) Pharmaceutical Ready to fill Pellets
b) Multiple Unit Pellet System (MUPS)
c) Tissue Bio Adhesive
d) Injectables (Small Volume Parenterals)
e) Oral Solid Dosages (Tablets & Capsules)
f) Liquid Orals (Syrups & Suspensions)
g) Dry Syrup (Powder)